Factors Influencing Oxalate Synthesis in Healthy Volunteers.

Urine oxalate excretion influences the risk of calcium oxalate kidney stone formation and has been reported to positively correlate with body mass index (BMI) and body weight. The two major sources of urine oxalate are dietary oxalate absorption and endogenous oxalate synthesis (EOS). In this study, we investigated the association between EOS, as estimated by oxalate content of 24-hour urine collected while consuming an ultra-low oxalate diet, and measures of body size and composition.

Hyperoxaluria: Diagnosis and Treatment.

Hyperoxaluria is categorized as either primary (PH), enteric (EH), or idiopathic (IH). The PHs are a group of ultra-rare genetic disorders resulting in oxalate overproduction that can result in end-stage renal disease (ESRD). Novel RNA inhibitory drugs are now available to treat PH that significantly reduced the risk of kidney stones.

Inducing Colonization Reduces Urinary Oxalate in Healthy Adults.

Introduction: Oxalate-degrading intestinal bacteria, including the oxalate-degrading specialist, have the potential to reduce urinary oxalate excretion in humans, and thus limit the risk of calcium oxalate kidney stone formation. The aim of this proof-of-concept study, which was performed in healthy adults, was to demonstrate that ingestion of live is safe, can establish sustainable gut colonization, and reduce urinary oxalate excretion.

Methods: Twenty-two healthy adults without a history of kidney stones and not colonized with ingested diets controlled in oxalate and calcium.

Eligibility of Living Kidney Donors with Kidney Stone Disease.

Introduction: Guidelines recommend that patients with a self-reported history of kidney stones or stones on imaging during living kidney donor (LKD) evaluation undergo 24-h urine stone risk testing. We examined eligibility decisions for LKD candidates at two high-volume academic transplant centers based on 24-h urine testing and imaging findings.

Methods: We identified potential LKDs with a self-reported history of kidney stones or stones identified on imaging, who underwent 24-h urine collection.

Metabolic dysfunction associated steatotic liver and kidney stones: what is going on?

Purpose Of Review: Metabolic dysfunction associated steatotic liver disease (MASLD) is increasing throughout the world, affecting nearly one in three individuals. Kidney stone disease, which is also increasing, is associated with MASLD. Common risk factors for both, including obesity, diabetes, dyslipidemia, hypertension, and metabolic syndrome, are likely drivers of this association.